Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Bernd Adami"'
Autor:
Khan Fareed Rahman, Florian Thieringer, Martin F. Sprinzl, Bernd Adami, Helmut Neumann, Helmut Neumann Sen, Peter R. Galle, Shakil Ahmed
Publikováno v:
Gastrointestinal Endoscopy. 87:AB365
Autor:
Florian Thieringer, Khan Fareed Rahman, Gian Eugenio Tontini, Bernd Adami, Peter R. Galle, Shakil Ahmed, Helmut Neumann, Helmut Neumann Sen
Publikováno v:
Gastrointestinal Endoscopy. 87:AB468
Autor:
Michael Heike, Michael Baldus, Christine Zanke, Peter R. Galle, Markus Moehler, Martin Schroeder, Peter Schwindt, Tanja Hoffmann, Peter Ehscheid, Horst Hohl, Helmut Burg, Bernd Adami, Ortwin Klein
Publikováno v:
Anti-Cancer Drugs. 14:79-85
The combination of irinotecan (CPT-11), bolus 5-fluorouracil (5-FU) and folinic acid (FA) (Saltz regimen) has recently been questioned as first-line chemotherapy for metastatic colorectal cancer after high early death rates due to gastrointestinal an
Autor:
Werner Godderz, Klaus Majer, Thomas Hoehler, Juergen Siebler, Carl C. Schimanski, Dimitri Flieger, Murad Abdelfattah, Stephan Kanzler, Peter R. Galle, Markus Moehler, Martin F. Sprinzl, Andreas Teufel, Bernd Adami
AIM: To investigate the efficacy and safety of cape-citabine plus irinotecan ± bevacizumab in advanced or metastatic colorectal cancer patients. METHODS: Forty six patients with previously untreated, locally-advanced or metastatic colorectal cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1221cde7abda302d9cd83f8a23644ce2
https://europepmc.org/articles/PMC2653366/
https://europepmc.org/articles/PMC2653366/
Autor:
Markus Moehler, Bernd Adami, M Schroeder, Andreas Teufel, Ophir D. Klein, Silke Steinmann, Peter R. Galle, Christiane Zanke, Jürgen Siebler, Thomas Höhler, Michael Heike, Herbert Hohl
Publikováno v:
BMC Cancer
BMC Cancer, Vol 4, Iss 1, p 38 (2004)
BMC Cancer, Vol 4, Iss 1, p 38 (2004)
Background Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer. However, in light of safety and efficacy concerns, the best combinatio
Autor:
Teufel, Andreas1 teufel@uni-mainz.de, Steinmann, Silke1 ssteis@t-online.de, Siebler, Jürgen1 siebler@mail.uni-mainz.de, Zanke, Christiane2 Vanessa.Wilsberg@web.de, Hohl, Herbert2 groeger-bicanic@1-med.klinik.uni-mainz.de, Adami, Bernd3 bernd.adami@onlinemed.de, Schroeder, M.4 groeger-bicanic@1-med.klinik.uni-mainz.de, Klein, O.5 moehler@1-med.klinik.unimainz.de, Höhler, Thomas1 hoehler@mail.uni-mainz.de, Galle, Peter R.1 galle@mail.uni-mainz.de, Heike, Michael1 stkd.mheike@dokom.net, Moehler, Markus1 moehler@mail.uni-mainz.de
Publikováno v:
BMC Cancer. 2004, Vol. 4, p38-8. 8p. 4 Charts, 2 Graphs.